Takeda Pharmaceutical Co. Ltd. has reported the first Phase III data for the investigational uterine fibroid treatment relugolix in Japanese patients in a study that is seen as a bellwether for larger international studies being undertaken by licensee Myovant Sciences Ltd.
The US firm licensed rights to the product outside Japan and certain other Asian countries in June 2016 for use...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)